Movement Alert｜Boston Scientific Intraday Rise 3.05% in Regular Trading, Shares React to Debate Over 2027 Headwinds After Recent Q3 Update

Market Focus11-02 23:38

On November 2, Boston Scientific rose 3.05% in Regular Trading, trading at $43.255/share, with turnover of $186 million.

The most recent market catalyst was an analyst note stating that weak conditions in the WATCHMAN franchise and Electrophysiology portfolio could create greater-than-expected headwinds for the company’s 2027 earnings baseline, though July restructuring savings may partially offset that pressure.

That view followed the company’s latest quarterly update: third-quarter adjusted EPS was $0.73 on revenue of $5.14 billion, both slightly above expectations, but full-year adjusted EPS guidance was cut to $3.16 to $3.18 and fourth-quarter adjusted EPS guidance of $0.77 to $0.79 trailed consensus. Reported commentary also indicated that the earlier guidance reset was largely anticipated because of the third-quarter cybersecurity incident.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment